### Cardiovascular and Diabetes Task Force Summary of In-Person Meeting #1

An in-person meeting of the Measure Applications Partnership (MAP) Cardiovascular and Diabetes Task Force was held on Thursday, June 21, 2012. For those interested in reviewing an online archive of the web meeting, please follow this link to the <u>meeting recordings.</u>

### Cardiovascular and Diabetes Task Force Members Attending:

Christine Cassel (Chair)	
Uri Adler, American Medical Rehabilitation	Robert Krughoff, Consumer's CHECKBOOK
Providers Association (substitute for Suzanne	
Snyder)	
Rhonda Anderson, American Hospital Association	Mark Metersky, Physician Consortium for
[phone]	Performance Improvement
Bruce Auerbach, American College of Emergency	Eugene Nelson [subject matter expert: Population
Physicians [phone]	Health]
Beth Averbeck, Minnesota Community	Peggy O'Kane, National Committee of Quality
Measurement	Assurance
Bruce Bagley, American Academy of Family	David Polakoff, American Medical Directors
Physicians	Association
Richard Bankowitz, Premier, Inc.	Michael Rapp, Centers for Medicare & Medicaid
	Services [phone]
Peter Briss [liaison: National Priorities Partnership]	Lance Roberts, Iowa Healthcare Collaborative
Paul Casale, American College of Cardiology	Marissa Schlaiffer, Academy of Managed Care
	Pharmacy
Mary George [liaison: Consensus Development	Joshua Seidman, Office of the National
Process]	Coordinator for HIT [phone]
Randall Krakauer, AETNA	James Walker [subject matter expert: Health
	IT/Patient Reported Outcome Measures]

The primary objectives of the meeting were to:

- Review task force charge, role within the MAP, and plan to complete the tasks;
- Identify priority performance measurement areas for diabetes and cardiovascular conditions;
- Establish diabetes family of measures; and
- Begin defining cardiovascular family of measures.

### Welcome and Review of Meeting Objectives

Led by Christine Cassel, Cardiovascular and Diabetes Task Force Chair, with additional presentation by Ann Hammersmith, National Quality Forum (NQF) General Counsel.

- Dr. Cassel welcomed the task force to the first convening and reviewed the meeting objectives.
- Dr. Cassel introduced Ms. Hammersmith, who explained conflicts of interest for MAP members and led disclosure of interest from the task force members

### **Establishing Families of Measures and Measure Gaps**

Led by Dr. Cassel, with additional presentations by Connie Hwang, NQF Vice President, and Aisha Pittman, NFQ Senior Program Director.

- Dr. Hwang presented the proposed MAP scope of work for 2012-2013 and the charge of the Cardiovascular and Diabetes Task Force.
- Ms. Pittman presented the approach used to identify families of measures, gaps, and phasing strategies.

### Primary Prevention of Diabetes and Cardiovascular Conditions

Led by Dr. Cassel, with presentation by Allen Leavens, NQF Senior Director.

- Dr. Leavens presented areas identified as high leverage opportunities per the Institute of Medicine 3I's Impact, Inclusiveness, and Improvability within the Patient-Centered Episode of Care Model.
- Since many of the key contributors to diabetes are also important to measure for cardiovascular disease, the group determined that some measures will apply to both families.
- In identifying primary prevention measures for the diabetes and cardiovascular families of measures (see attachment), the task force emphasized the essential opportunities through community-level prevention to increase awareness, adherence, and disease control to move the nation in the direction of healthy lifestyles. Process and intermediate outcomes measures are needed for early identification and management of disease, such as blood pressure and cholesterol control.

### Diabetes Evaluation, Ongoing Management, and Complications

Led by Dr. Cassel, with presentation by Dr. Leavens.

- Dr. Cassel introduced the episode of care model modified for the diabetic patient, and Dr. Leavens presented areas identified as high-leverage opportunities for diabetes management using the IOM's 3I's framework.
- In identifying the diabetes family of measures (see attachment), the task force discussed early diagnosis and treatment of diabetes to improve care and modify patient behavior to prevent complications and undesirable outcomes.
- The group highlighted some available measures are not suitable or sufficient for all populations. For example, pediatric patients should be screened for cardiovascular disease and diabetes when appropriate, though not all measures apply. Thresholds established in measure specifications might better serve as ranges for control of blood pressure, cholesterol, or hemoglobin A1C and some age limits should be expanded to measure the entire population at risk.
- The task force made a conscious effort to choose a parsimonious set of measures and limit the burden of measurement.
- As the group discussed diabetes complications, members expressed a need for measures focusing on personcentered care, shared decision-making, and outcomes. In addition, the value and trade-offs of composite measures are not fully known, including their ability to drive improvement further than individual measures or providing a more comprehensive person-centered picture or measures of systems, teams, and providers for the whole patient.
- The task force considered the potential adverse impacts of measurement, such as discouraging patients from seeking care or providers treating patients in inappropriate care settings, such as routine care in the urgent care or emergency department, to avoid penalties associated with quality measurement. For patients who have chronic conditions, emergency department visits or some complications and exacerbations of disease may not be avoidable; therefore, measures of emergency department visits may be inappropriate or too general in some cases.
- The group identified patient level of engagement and informed decision-making as gaps in measurement.

### Cardiovascular Care

Led by Dr. Cassel, with presentation by Dr. Leavens.

• Dr. Cassel introduced the episode of care model modified for acute and chronic cardiovascular care. Dr. Leavens presented areas identified as high-leverage opportunities of cardiovascular care, including Stroke, Ischemic heart Disease, Heart Failure, and Atrial Fibrillation, using the IOM's 3I's framework.

### Stroke

Led by Dr. Cassel

- Dr. Cassel led the task force discussion on the topic of Stroke care and measure selection.
- The task force determined to discuss Stroke more thoroughly at the next in-person task force meeting on July 17, 2012.

### Affordability

Led by Dr. Cassel, with presentations by Taroon Amin, NQF Senior Director, and Ashley Wilbon, NQF Senior Project Manager.

- Dr. Cassel discussed the changing environment of resource use and cost measures in health care.
- Mr. Amin and Ms. Wilbon presented the results of the recent endorsement project completed by NQF on resource use measures.
- The task force discussed the importance of cost and resource use measures to patients, the relationship of cost measures and value of healthcare, and the necessity of cost measures to directly link to quality of care.
- The task force will conduct additional work on choosing costs and resource use measures for the cardiovascular and diabetes families of measures prior to the next in-person meeting, July 17, 2012.

### Conclusion

The meeting concluded with a discussion of next steps. The next meeting of the Cardiovascular and Diabetes Task Force will be an in-person meeting on July 17, 2012.

### Primary Prevention of Cardiovascular Conditions and Diabetes Measures Selected for Family

NQF # and	Measure	Care Settir	Ig	Level of Analysis	MAP Findings	
Status						
Smoking Cessation/Tobacco Use						
<u>0028</u>	Measure pair: a. Tobacco Use	Clinician		Individual		
<b>Endorsed</b>	Assessment, b. Tobacco	Office/Clinic				
	Cessation Intervention					
<u>1406</u>	Risky Behavior Assessment or	Clinician		Group/Practice,		
Endorsed	Counseling by Age 13 Years	Office/Clinic,		Individual, National,		
		Outpatient		Regional, Team		
1651	TAM-1 Tobacco Use Screening	Behavioral		Facility, National		
Recommend		Health/Psychia	atric:			
ed		Inpatient,				
		Hospital/Acute	e Care			
		Facility				
1654	TAM-2 Tobacco Use Treatment	Behavioral		Facility, National		
Deferred	Provided or Offered	Health/Psychia	atric:			
		Inpatient,				
		Hospital/Acute	e Care			
		Facility				
		Lifestyle Manag	ement			
<u>0421</u>	Adult Weight Screening and	Allsettings		Can be measured at		
Endorsed	Follow-Up			all levels		
<u>0024</u>	Body Mass Index (BMI) 2	Clinician		Individual		
Endorsed	through 18 Years of Age	Office/Clinic				
		Blood Pressu	ire			
<u>0018</u>	Controlling High Blood Pressure	All settings,		Group/Practice,	Public commenters	
<b>Endorsed</b>		Ambulatory Su	rgery	Individual	supported inclusion.	
		Center (ASC),				
		Clinician				
		Office/Clinic,				
		Hospital/Acute				
		Facility, Urgen	t			
		Care, Clinician				
		Office/Clinic				
GAPS			MAP Findings			
Lipid Control	,		Publi	Public commenters supported the need for lipid		
				control measures broadly, and they encouraged		
	tim		timel	timely development of a control measure applicable		
	acr		acros	across the population.		

NQF # and Status	Measure	Care Setting	Level of Analysis	MAP Findings	
Smoking Cessation	Outcomes of smoking cess interventions	sation			
Lifestyle Managemen t	<ul> <li>Physical activity/exercise, across all levels of analysis</li> </ul>	s and settings He	Public commenters suggested that MAP consider Health Partner's Optimal Lifestyle measure to fill the gap. MAP recommends that the measure be brought forward for NQF endorsement.		
Cardiometa bolic Risk	Across all levels of analysi	s and settings			

### **Diabetes Measures Selected for Family**

NQF # and Status	Measure	Care Setting	Level of Analysis	MAP Findings	
0575 Endorsed	Comprehensive Diabetes Care: HbA1c Control (<8.0%)	Clinician Office/Clinic	Group/Practice, Health Plan, Individual, Integrated Delivery System, National, Regional, State	One public commenter suggested HbA1c control use stricter standards, such as those developed by the American Association of Clinical Endocrinologists.	
0064 Endorsed	Diabetes Measure Pair: A Lipid management: low density lipoprotein cholesterol (LDL-C) <130, B Lipid management: LDL- C <100	Clinician Office/Clinic	Group/Practice, Health Plan, Individual, Integrated Delivery System, National, Regional, State	MAP noted that forthcoming National Heart, Lung and Blood Institute (NHLBHI) guidelines could change the low density lipoprotein targets. Adjusting measures to align with new guidelines will be addressed through the NQF-endorsement process.	
Composites					
0729 Endorsed	Optimal Diabetes Care	Clinician Office/Clinic	Group/Practice, Integrated Delivery System	MAP suggested that both diabetes composites consider	
0731 Endorsed	Comprehensive Diabetes Care	Clinician Office/Clinic	Group/Practice, Health Plan, Individual	addressing body mass index.	
GAPS MAP Findings					

NQF # and Status	Measure	Care Setting	Level of Analysis	MAP Findings	
Glycemic Control	<ul> <li>Measures addressing glycemic control for complex patients (e.g., geriatric population, multiple chronic conditions) at the clinician, facility, and system levels of analysis</li> <li>Pediatric glycemic control</li> <li>Measures addressing glycemic control at the facility level</li> </ul>		Public commenters supported expansion of levels of analysis for glycemic control.		
Lipid Control	<ul> <li>Measures addressing lipid control at the facility level of analysis</li> </ul>		Public commenters supported expansion of levels of analysis for lipid control.		
Sequelae of Exacerbatio ns	Measures addressing sequelae of diabetes exacerbations at all levels of analyses		Public commenters recommended inclusion of measures that address retinopathy (NQF #0055, 0088, 0089). MAP noted that measure #0055 is included in composite #0729, and that these measures should be considered for federal programs (i.e., PQRS), as appropriate, to meet the program needs.		